Hengrui Pharma(SH:600276) 智通财经网·2025-12-28 09:29Group 1 - The company Heng Rui Medicine (600276.SH) has signed an exclusive licensing agreement with Hansoh Pharmaceutical Group Co., Ltd. to license its SHR6508 project [1] - SHR6508 is a novel calcium-sensing receptor allosteric modulator intended for the treatment of secondary hyperparathyroidism in adult patients undergoing hemodialysis, currently in Phase III clinical trials [1] - The company’s paricalcitol soft capsule product is expected to be approved for market launch by the National Medical Products Administration in November 2025 [1] Group 2 - Hansoh Pharmaceutical and its subsidiary, Jiangsu Hengrui Pharmaceutical Group Co., Ltd., are controlled by the spouse of the company's actual controller and chairman, Sun Piaoyang, making them related parties under listing rules [2] - Hansoh Pharmaceutical is a leading innovation-driven pharmaceutical company in China, focusing on major disease treatment areas such as oncology, anti-infection, central nervous system, metabolism, and autoimmune diseases [2]